Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-18 11:48 am Purchase |
2025-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BlackRock Inc. BLK |
179,125 3.000% |
179,125 (New Position) |
Filing History |
| 2025-01-31 10:09 am Sale |
2024-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
The Vanguard Group | 273,363 4.800% |
-7,994 (-2.84%) |
Filing History |
| 2024-11-12 5:59 pm Unchanged |
2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
The Vanguard Group | 281,358 5.000% |
0 (Unchanged) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BlackRock Inc. BLK |
373,689 6.700% |
0 (Unchanged) |
Filing History |
| 2024-11-04 2:15 pm Purchase |
2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
The Vanguard Group | 281,358 5.000% |
281,358 (New Position) |
Filing History |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BlackRock Inc. BLK |
373,689 6.700% |
101,664 (+37.37%) |
Filing History |
| 2024-02-14 7:36 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 383,148 6.700% |
38,860 (+11.29%) |
Filing History |
| 2024-02-14 4:44 pm Purchase |
2022-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ACORN BIOVENTURES, L.P. | 591,862 9.990% |
591,862 (New Position) |
Filing History |
| 2024-02-14 4:32 pm Sale |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Lincoln Park Capital Fund LLC | 53,338 0.947% |
-6,998 (-11.60%) |
Filing History |
| 2024-02-13 6:55 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BCLS I Investco, LP | 563,859 11.000% |
157,109 (+38.63%) |
Filing History |
| 2024-02-07 5:09 pm Sale |
2024-01-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BlackRock Inc. BLK |
272,025 4.900% |
-8,559 (-3.05%) |
Filing History |
| 2024-01-31 2:08 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BlackRock Inc. BLK |
280,584 5.000% |
244,768 (+683.40%) |
Filing History |
| 2024-01-16 4:18 pm Sale |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Millennium Management LLC | 55,477 1.000% |
-220,150 (-79.87%) |
Filing History |
| 2024-01-08 10:26 am Sale |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Empery Asset Management, LP | 151,654 2.650% |
-54,969 (-26.60%) |
Filing History |
| 2023-06-16 4:04 pm Purchase |
2023-06-09 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Millennium Management LLC | 275,627 5.200% |
275,627 (New Position) |
Filing History |
| 2023-05-26 3:03 pm Purchase |
2023-05-18 | 13D | X4 Pharmaceuticals, Inc. XFOR |
Growth Equity Opportunities 18 VGE LLC | 524,760 9.990% |
120,200 (+29.71%) |
Filing History |
| 2023-02-14 5:24 pm Purchase |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 344,288 8.200% |
283,077 (+462.46%) |
Filing History |
| 2023-02-14 4:18 pm Sale |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Point72 Asset Management, L.P. | 30,441 1.300% |
-23,999 (-44.08%) |
Filing History |
| 2023-02-14 11:26 am Sale |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Ikarian Capital LLC | 11,638 0.300% |
-63,845 (-84.58%) |
Filing History |
| 2023-02-14 06:34 am Purchase |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BCLS I Investco, LP | 406,750 11.000% |
310,532 (+322.74%) |
Filing History |